Ligand to Acquire XOMA Royalty for $739M, Expanding Royalty Portfolio
Event summary
- Ligand Pharmaceuticals to acquire XOMA Royalty for $39.00 per share in cash, totaling $739M.
- Transaction expected to close in Q3 2026, subject to shareholder and regulatory approvals.
- Acquisition adds over 120 commercial, clinical, and preclinical stage assets to Ligand’s portfolio.
- Ligand raises 2026 adjusted EPS guidance to $8.50-$9.50, up from $8.00-$9.00.
- Deal expected to be accretive by $1.50 per share to adjusted EPS in 2027.
The big picture
This acquisition solidifies Ligand’s position as a leading biopharma royalty aggregator, expanding its portfolio to over 200 assets. The deal reflects a broader industry trend of consolidation among royalty aggregators seeking to diversify their portfolios and enhance long-term growth. The inclusion of seven new commercial products and a robust pipeline of late-stage assets positions Ligand to capitalize on upcoming regulatory and clinical catalysts.
What we're watching
- Integration Challenges
- The pace at which Ligand can integrate XOMA Royalty’s portfolio and realize synergies will determine the deal’s success.
- Regulatory Approvals
- Whether the transaction receives timely approvals from regulators and XOMA Royalty shareholders.
- Financial Performance
- How the acquisition impacts Ligand’s long-term growth profile and ability to meet updated financial guidance.
Related topics